Skip to content

Spice II Plus: Acute toxicity of new synthetic cannabinoids and stimulant drugs

Spice II Plus: Acute toxicity of new synthetic cannabinoids and stimulant drugs - Spice II Plus

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00005093
Enrollment
250
Registered
2013-07-24
Start date
2013-08-14
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute poisoning through new designer drugs T40.7 T43.9

Interventions

Group 1: Two Parts: Part 1: Retrospective inquiry in the poison control center Freiburg database, regarding cases of human exposure to new designer drugs (cathinone derivatives and other drugs not li

Sponsors

Vergiftungs-Informations-Zentrale, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Exposure to new synthetic Designer Drugs and other (unknown) drugs especially cathinone derivatives and Research chemicals that were not listed in the PCC Databank till 2007, as well as sythetic cannabinoids - Consultation of a medical/emergency Unit - Agreement to participation in Survey

Exclusion criteria

Exclusion criteria: - Non-professional inquiry - Disagreement to participation in Survey

Design outcomes

Primary

MeasureTime frame
Primary objective: To find out which new drugs lead to consultation of poison control centers and emergency units because of undesirable effects. To correlate symptoms and outcome to the substances found in the toxicological analysis. Toxicological assessment of the drug. To identify the circumstances of consumption that possibly enhance toxicity.

Secondary

MeasureTime frame
Secondary objective: -To discover interaction with other drugs and medication. - To improve the quality of consultation during emergency

Countries

Germany

Contacts

Public ContactUwe Stedtler

Vergiftungs-Informations-Zentrale

uwe.stedtler@uniklinik-freiburg.de+ 49 761/19240

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026